Fusion Antibodies（FAB）株式概要フュージョン・アンティボディーズ社（Fusion Antibodies plc）は、受託研究機関として、主にがんや感染症を対象とした組換えタンパク質や抗体の研究、開発、製造をイギリス、その他のヨーロッパ諸国、北米、そして国際的に行っている。 詳細FAB ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長1/6過去の実績0/6財務の健全性3/6配当金0/6報酬収益は年間14.57%増加すると予測されています 過去5年間の収益は年間3%増加しました。 リスク分析現在は利益が出ておらず、今後3年間で利益が出る見込みはない 最新の財務報告は6か月以上前のものである 意味のある時価総額がありません ( £13M )意味のある収益がありません ( £2M )すべてのリスクチェックを見るFAB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW478,504 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA478,504 investors already sharing narrativesYour Fair ValueUK£Current PriceUK£0.1032.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m5m2016201920222025202620282031Revenue UK£3.2mEarnings UK£401.0kAdvancedSet Fair ValueView all narrativesFusion Antibodies plc 競合他社Proteome SciencesSymbol: AIM:PRMMarket cap: UK£6.3mIXICOSymbol: AIM:IXIMarket cap: UK£17.4mhVIVOSymbol: AIM:HVOMarket cap: UK£47.4mOxford BioDynamicsSymbol: AIM:OBDMarket cap: UK£4.7m価格と性能株価の高値、安値、推移の概要Fusion Antibodies過去の株価現在の株価UK£0.1052週高値UK£0.2152週安値UK£0.095ベータ1.221ヶ月の変化-4.55%3ヶ月変化-27.59%1年変化-25.00%3年間の変化50.00%5年間の変化-91.76%IPOからの変化-91.50%最新ニュースお知らせ • Jun 22Fusion Antibodies Receives Notice of Allowance for Canadian Patent Application Covering Antibody Library and MethodFusion Antibodies plc announced that the Canadian Intellectual Property Office has issued a notice of allowance in respect of the Company's Canadian patent application no. 3,115,150. The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The patent, once granted, is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation. The Company is also progressing additional patent applications in respect of the OptiMAL Library in Canada and several other territories worldwide including Europe and China. Receipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.お知らせ • Jun 15Fusion Antibodies plc Receives Grant Funding from UK Research & Innovation and InvestNIFusion Antibodies plc provided the following update on the progress of the InnovateUK Launchpad grant in collaboration with Queen's University Belfast. The primary purpose of the Grant is to develop a humanised antibody targeting and activating the DR5 protein on cancer cells for the treatment of cancers resistant to other therapies, with the aim of producing a clinic-ready therapeutic asset capable of being licensed to a third-party pharmaceutical or biotechnology company. The Grant funds are being provided by UK Research & Innovation and InvestNI. The DR5 antibody has been successfully humanised from the initial rabbit antibody using the Company's proprietary CDRx humanisation platform, and a number of more complex structural variants have been developed and assessed in parallel. All variants are producing positive results in tumour cell death assays, demonstrating the Company's expertise with advanced antibody engineering. The gene encoding the lead humanised antibody has been successfully inserted and developed into a stable cell line suitable for large-scale manufacture. This cell line development part of the process made use of new microfluidic technology housed at the Future Medicines Institute and reduced the process timeline by approximately 50% to around four months. Given the progress made to date, UK Research & Innovation has agreed to extend the project from its originally targeted completion date of October 31, 2026 to December 31, 2026. Over the remaining months of the project, the DR5 humanised antibody and selected variants will undergo further pre-clinical evaluation in relevant cancer models. Positive results are expected to support a patent application covering the antibody family and could lead to the creation of a licensable therapeutic asset for further development and commercialisation by an industry partner. Total Grant funding is over GBP 808,000 of which up to GBP 545,000 of direct non-dilutive funding available to Fusion. Eligible costs include Labour, Overheads and Materials. The project has provided valuable Case Study data for several of Fusion's key technologies including CDRx humanisation, complex protein engineering capability, more rapid cell line development, and the potential to generate a licensable asset. A formal Collaboration Agreement has been signed by Fusion and Queen's University Belfast.New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£927k net loss next year). Share price has been volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.1m). Market cap is less than US$100m (UK£15.3m market cap, or US$20.5m).New Risk • Feb 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£789k net loss next year). Share price has been volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.2m). Market cap is less than US$100m (UK£16.9m market cap, or US$23.1m).Reported Earnings • Nov 27First half 2026 earnings released: UK£0.005 loss per share (vs UK£0.008 loss in 1H 2025)First half 2026 results: UK£0.005 loss per share (improved from UK£0.008 loss in 1H 2025). Revenue: UK£838.0k (down 31% from 1H 2025). Net loss: UK£512.0k (loss narrowed 33% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Nov 21Fusion Antibodies plc to Report First Half, 2026 Results on Nov 24, 2025Fusion Antibodies plc announced that they will report first half, 2026 results on Nov 24, 2025最新情報をもっと見るRecent updatesお知らせ • Jun 22Fusion Antibodies Receives Notice of Allowance for Canadian Patent Application Covering Antibody Library and MethodFusion Antibodies plc announced that the Canadian Intellectual Property Office has issued a notice of allowance in respect of the Company's Canadian patent application no. 3,115,150. The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The patent, once granted, is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation. The Company is also progressing additional patent applications in respect of the OptiMAL Library in Canada and several other territories worldwide including Europe and China. Receipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.お知らせ • Jun 15Fusion Antibodies plc Receives Grant Funding from UK Research & Innovation and InvestNIFusion Antibodies plc provided the following update on the progress of the InnovateUK Launchpad grant in collaboration with Queen's University Belfast. The primary purpose of the Grant is to develop a humanised antibody targeting and activating the DR5 protein on cancer cells for the treatment of cancers resistant to other therapies, with the aim of producing a clinic-ready therapeutic asset capable of being licensed to a third-party pharmaceutical or biotechnology company. The Grant funds are being provided by UK Research & Innovation and InvestNI. The DR5 antibody has been successfully humanised from the initial rabbit antibody using the Company's proprietary CDRx humanisation platform, and a number of more complex structural variants have been developed and assessed in parallel. All variants are producing positive results in tumour cell death assays, demonstrating the Company's expertise with advanced antibody engineering. The gene encoding the lead humanised antibody has been successfully inserted and developed into a stable cell line suitable for large-scale manufacture. This cell line development part of the process made use of new microfluidic technology housed at the Future Medicines Institute and reduced the process timeline by approximately 50% to around four months. Given the progress made to date, UK Research & Innovation has agreed to extend the project from its originally targeted completion date of October 31, 2026 to December 31, 2026. Over the remaining months of the project, the DR5 humanised antibody and selected variants will undergo further pre-clinical evaluation in relevant cancer models. Positive results are expected to support a patent application covering the antibody family and could lead to the creation of a licensable therapeutic asset for further development and commercialisation by an industry partner. Total Grant funding is over GBP 808,000 of which up to GBP 545,000 of direct non-dilutive funding available to Fusion. Eligible costs include Labour, Overheads and Materials. The project has provided valuable Case Study data for several of Fusion's key technologies including CDRx humanisation, complex protein engineering capability, more rapid cell line development, and the potential to generate a licensable asset. A formal Collaboration Agreement has been signed by Fusion and Queen's University Belfast.New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£927k net loss next year). Share price has been volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.1m). Market cap is less than US$100m (UK£15.3m market cap, or US$20.5m).New Risk • Feb 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£789k net loss next year). Share price has been volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.2m). Market cap is less than US$100m (UK£16.9m market cap, or US$23.1m).Reported Earnings • Nov 27First half 2026 earnings released: UK£0.005 loss per share (vs UK£0.008 loss in 1H 2025)First half 2026 results: UK£0.005 loss per share (improved from UK£0.008 loss in 1H 2025). Revenue: UK£838.0k (down 31% from 1H 2025). Net loss: UK£512.0k (loss narrowed 33% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Nov 21Fusion Antibodies plc to Report First Half, 2026 Results on Nov 24, 2025Fusion Antibodies plc announced that they will report first half, 2026 results on Nov 24, 2025お知らせ • Nov 04Fusion Antibodies plc Provides an Update to the OptiMal ProjectFusion Antibodies plc provides an update to the OptiMAL project being performed under the collaboration agreement with the National Cancer Institute, details of which were originally announced on 28 November 2023. Having already demonstrated superior single digit nM affinities for antibodies against protein targets, as detailed in the announcement on 17 September 2025, the Company can report that OptiMAL has been now shown to be similarly successful with smaller peptide targets. Peptides are often used as antigens as they can be designed to represent specific epitopes (regions of the protein) for the antibodies generated. They are also easier and more cost effective to synthesize. However, they are less immunogenic which can result in poorer antibodies. This is not the case with OptiMAL as no immune response is required. This evidence will better enable Fusion to propose the use of OptiMAL for a wider range of targets, thereby broadening the accessible market and increasing revenue potential. The next steps are to test the antibodies in cell-based assays at the NCI, to evaluate their potential to become therapeutic drug candidates. This latest finding provides further validation of OptiMAL as a platform for the isolation of specific antibodies against proteins and peptides and places the Company on track for the commercial launch of OptiMAL at the Antibody Engineering and Therapeutics conference in December 2025. Work continues within Fusion to further optimise and expand the OptiMAL platform. NCI, part of the US National Institutes of Health, is the US federal government's principal agency for cancer research and training. Pursuant to the Agreement, Fusion has provided NCI with access to OptiMAL for use in the discovery of novel antibodies against targets selected by NCI. This Agreement is due to continue until November 2025, however, the NCI has asked to extend its use of the OptiMAL platform for use against further targets in the coming years. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.お知らせ • Sep 22Fusion Antibodies plc, Annual General Meeting, Oct 16, 2025Fusion Antibodies plc, Annual General Meeting, Oct 16, 2025. Location: the offices of fusion antibodies plc, 1 springbank road, springbank industrial estate, belfast bt17 0ql, United KingdomReported Earnings • Sep 05Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: UK£0.018 loss per share (improved from UK£0.039 loss in FY 2024). Revenue: UK£1.97m (up 73% from FY 2024). Net loss: UK£1.71m (loss narrowed 22% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Jul 25Fusion Antibodies plc Announces That the United States Patent and Trademark Office Has Published A Patent Issue Notification in Respect of Patent Application No. 17/287,441Fusion Antibodies plc announces that the United States Patent and Trademark Office has published a patent issue notification (the "Issue Notification") in respect of the Company's patent application no. 17/287,441 . A patent issue notification is a document informing an applicant that their patent application has been approved and is scheduled to be granted. The Issue Notification indicates that the patent will be granted on 5 August 2025. The Patent Application, entitled "Antibody Library and Method", concerns the library of antibodies that is currently screened within Fusion's OptiMAL® platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide "Opti" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation. Further patent applications and examination processes are continuing in several other territories worldwide including Europe, China and Japan.New Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£7.56m market cap, or US$10.2m).お知らせ • May 23Fusion Antibodies plc Provides Update on U.S. Patent for OptimalFusion Antibodies plc announced that the United States Patent and Trademark Office has issued a notice of allowance in respect of the Company's U.S. patent application no. 17/287,441. The Patent Application entitled "Antibody Library and Method", concerns the library of antibodies that is currently screened within Fusion's OptiMAL platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide "Opti" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation. Receipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.New Risk • Apr 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£7.71m market cap, or US$10.3m).お知らせ • Mar 18Fusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.172153 million.Fusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.172153 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,949,208 Price\Range: £0.0675 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,416,020 Price\Range: £0.0675 Transaction Features: Subsequent Direct Listingお知らせ • Jan 31Fusion Antibodies plc Provides an Update on the Optimal Validation ProjectFusion Antibodies plc provided an update on the OptiMAL® validation project being performed under the collaboration agreement (the "Agreement") with the National Cancer Institute ("NCI"). The validation project is progressing as planned and, using Fusion's OptiMAL® Library, the NCI has identified a number of antibody expressing cells that positively bind to their targets of interest. Fusion will extract and sequence the DNA encoding for the antibodies from these cells for verification of binding and further analyses. This analysis will take several months. The Company has received the first batch of cells from the NCI that have been isolated from the OptiMAL® Library for this validation work and additional batches will be shipped subsequently. Fusion is undertaking this work on a goodwill basis to assist the validation of the OptiMAL® Library. The NCI will continue the process of identifying more positive cells against their various targets and the Company also anticipates assisting in the analysis of the antibodies produced from these cells. NCI, part of the US National Institutes of Health, is the US federal government's principal agency for cancer research and training. Pursuant to the Agreement, details of which were announced by the Company on 28 November 2023, Fusion has provided NCI with access to OptiMAL® for use in the discovery of novel antibodies against targets selected by NCI.Reported Earnings • Nov 25First half 2025 earnings released: UK£0.008 loss per share (vs UK£0.029 loss in 1H 2024)First half 2025 results: UK£0.008 loss per share (improved from UK£0.029 loss in 1H 2024). Revenue: UK£1.21m (up 123% from 1H 2024). Net loss: UK£758.0k (loss narrowed 44% from 1H 2024).お知らせ • Nov 20Fusion Antibodies plc to Report First Half, 2025 Results on Nov 19, 2024Fusion Antibodies plc announced that they will report first half, 2025 results on Nov 19, 2024New Risk • Sep 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.8m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (UK£3.86m market cap, or US$5.18m). Minor Risk Revenue is less than US$5m (UK£1.1m revenue, or US$1.5m).お知らせ • Sep 12Fusion Antibodies plc, Annual General Meeting, Oct 08, 2024Fusion Antibodies plc, Annual General Meeting, Oct 08, 2024. Location: the offices of fusion antibodies, 1 springbank road, springbank industrial estate, belfast, bt17 0ql, United KingdomReported Earnings • Sep 06Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: UK£0.039 loss per share (improved from UK£0.10 loss in FY 2023). Revenue: UK£1.14m (down 61% from FY 2023). Net loss: UK£2.23m (loss narrowed 14% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 26%.New Risk • Jun 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (UK£3.19m market cap, or US$4.04m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (7.2% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.0m).お知らせ • Feb 14+ 1 more updateFusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.375 million.Fusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.375 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 34,375,000 Price\Range: £0.04 Transaction Features: Subsequent Direct ListingReported Earnings • Dec 07First half 2024 earnings released: UK£0.023 loss per share (vs UK£0.043 loss in 1H 2023)First half 2024 results: UK£0.023 loss per share. Revenue: UK£541.0k (down 71% from 1H 2023). Net loss: UK£1.36m (loss widened 22% from 1H 2023).お知らせ • Dec 05Fusion Antibodies plc to Report First Half, 2024 Results on Dec 04, 2023Fusion Antibodies plc announced that they will report first half, 2024 results on Dec 04, 2023お知らせ • Dec 04Fusion Antibodies plc Provides Revenue Guidance for the Fiscal Year 2024Fusion Antibodies plc provided revenue guidance for the fiscal year 2024. For the year, the revenues are expected to be significantly weighted towards the second half of the financial year. This is supported by the revenue growth trend observed through first half of fiscal year 2024 and the marked growth in its sales opportunities pipeline over the last six months.お知らせ • Nov 09Fusion Antibodies plc Provides Earnings Guidance for the First Half of Fiscal Year 2024Fusion Antibodies plc provided earnings guidance for the first half of fiscal year 2024. For the period, the company expects revenue to be behind current market expectations, at not less than £541,000.New Risk • Oct 01New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Market cap is less than US$10m (UK£3.27m market cap, or US$3.99m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Revenue is less than US$5m (UK£2.9m revenue, or US$3.5m).Reported Earnings • Oct 01Full year 2023 earnings released: UK£0.10 loss per share (vs UK£0.046 loss in FY 2022)Full year 2023 results: UK£0.10 loss per share (further deteriorated from UK£0.046 loss in FY 2022). Revenue: UK£2.90m (down 40% from FY 2022). Net loss: UK£2.60m (loss widened 116% from FY 2022).お知らせ • Oct 01Fusion Antibodies plc Announces Sonya Ferguson, Non-Executive Director, Will Not Be Seeking Re-Election At the AGMFusion Antibodies plc announced that Sonya Ferguson, Non-executive Director, will not be seeking re-election at the AGM to be held on 27 October 2023, as she has decided to pursue another business opportunity. She will cease to be a Director of the Company at the close of the AGM.お知らせ • Sep 29Fusion Antibodies plc, Annual General Meeting, Oct 27, 2023Fusion Antibodies plc, Annual General Meeting, Oct 27, 2023, at 10:00 Coordinated Universal Time. Location: Springbank Industrial Estate, 1 Springbank Rd Dunmurry Belfast United Kingdomお知らせ • Aug 24Fusion Antibodies plc Appoints Stephen Smyth as Interim Chief Financial Officer of the Company with Immediate EffectFusion Antibodies plc announces that Stephen Smyth has been appointed as interim Chief Financial Officer of the Company with immediate effect. Stephen has over 25 years' experience working in audit & accounting, finance, and operations management within both the public accounting and commercial sectors. Stephen's previous roles include acting as Chief Financial Officer at Sera Global LP, as well as holding senior finance functions at Cormark Securities Inc. and at PricewaterhouseCoopers (PwC) LLP. Stephen is a chartered accountant and is currently a partner at FPM, a Chartered Accountancy practice with offices throughout the Republic of Ireland and Northern Ireland, including Belfast. At FPM, he provides virtual finance function solutions to clients ranging from start-ups to private equity backed multinationals. As part of the ongoing efforts to preserve cash, Fusion will be utilising the services of Stephen on a part-time basis, supported by a team at FPM, who will provide the Company with outsourced finance function services. It is anticipated that the Company will utilise the services of Stephen and FPM until such time that the trading recovers to levels that would support the appointment of a permanent CFO and in-house finance function.お知らせ • Aug 21Fusion Antibodies plc Announces an Update on the AI/ML-Ab Service OfferingFusion Antibodies plc announced an update on the Company's AI/ML-Ab (pronounced AIM-Lab) service offering. On 19 May 2023, the Company announced that it had signed memoranda of understanding with two AI/ML (artificial intelligence and machine learning) companies. The Company announced that is has now signed an agreement with the first of the companies, a leading US-based AI/ML business, to support Fusion's new AI/ML-Ab service offering. Pursuant to the Agreement, it is envisaged that both parties will co-market the combined service offerings covering both the in silico AI/ML design of antibodies and their production and evaluation in vitro. Each party to the Agreement will be entitled to a fee for any new business introduced to the other. Both parties have already combined to begin commercialisation of the offering and are processing multiple leads derived by both entities. AI/ML-Ab combines the latest AI enabled technology for in silico design of antibody sequences with Fusion's established core expertise in antibody expression and evaluation. Furthermore, AI/ML-Ab can also employ Fusion's recently announced proprietary Mammalian Display platform to enable screening of focused libraries derived from AI/ML design outputs. By combining the two approaches, clients will be able to screen thousands or even millions of sequences rather than the tens or hundreds to which such projects tend to be restricted. Increasing the number of sequences to be screened by a factor of 1,000 or more significantly enhances the prospects of finding the most appropriate leads from AI/ML discovery projects, not only de-risking this novel cutting-edge approach to antibody discovery but also achieving this at a significantly lower cost per sequence. Fusion collaborates with its clients in every stage of pre-clinical antibody development, with decades of experience and unique proprietary platforms. A fully integrated end-to-end service from therapeutic target nomination and discovery through to stable cell line development in readiness for GMP production is also available. The Company is continuing to work on other aspects of the OptiMAL programme, and in particular the development of the fully human antibody library.お知らせ • Feb 09Fusion Antibodies plc Launches New Commercial Service from Its R&D ProgrammeFusion Antibodies plc announced that is has launched a new commercial service from its R&D programme, named Mammalian Display, for high volume mammalian cell surface expression and screening of antibodies. Mammalian Display is the first service from the Company's ongoing OptiMAL programme which Fusion has commercialised and is now offering to clients. The service is particularly suited to companies specialising in the identification of therapeutic antibodies from focussed libraries of sequences, such as would be required by those entities using artificial intelligence or machine learning which can require the expression and screening of small libraries of tens of thousands of antibodies. Fusion collaborates with its clients in every stage of pre-clinical antibody development, with decades of experience and unique proprietary platforms. A fully integrated end-to-end service from therapeutic target nomination and discovery through to stable cell line development in readiness for GMP production is also available. Initial market research that the Company has conducted with AI/ML experts has confirmed that there is a need for expression of focussed libraries of antibodies in the way delivered by the Mammalian Display service. The Company is continuing to work on other aspects of the OptiMAL programme, and in particular the development of the fully human antibody library.Reported Earnings • Dec 06First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.023 loss in 1H 2022)First half 2023 results: UK£0.043 loss per share (further deteriorated from UK£0.023 loss in 1H 2022). Revenue: UK£1.86m (down 24% from 1H 2022). Net loss: UK£1.12m (loss widened 91% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 19% per year.お知らせ • Nov 24Fusion Antibodies plc to Report First Half, 2023 Results on Dec 05, 2022Fusion Antibodies plc announced that they will report first half, 2023 results on Dec 05, 2022Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Member of Scientific Advisory Panel & Independent Non-Executive Director Matthew Baker was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 02Fusion Antibodies plc, Annual General Meeting, Sep 23, 2022Fusion Antibodies plc, Annual General Meeting, Sep 23, 2022, at 10:00 Coordinated Universal Time. Location: in The Malone Hotel, 60 Eglantine Avenue, Malone Road Belfast, BT9 6DY Belfast Irelandお知らせ • Sep 01Fusion Antibodies plc Announces Director ChangesFusion Antibodies plc announced Tim Watts, Non-executive Director since December 2017, has informed the Board of his intention to retire and, therefore, will not be seeking re-election at the AGM. He will cease to be a Director of the Company at the close of the AGM. Colin Walsh, Non-executive Director will take up the position of Chair of the Company's Audit Committee in place of Tim Watts.分析記事 • Aug 31Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • Aug 23Full year 2022 earnings released: UK£0.046 loss per share (vs UK£0.11 loss in FY 2021)Full year 2022 results: UK£0.046 loss per share (up from UK£0.11 loss in FY 2021). Revenue: UK£4.80m (up 15% from FY 2021). Net loss: UK£1.20m (loss narrowed 59% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.お知らせ • Aug 09Fusion Antibodies plc Announces Bispecific Designs Patent ApplicationFusion Antibodies plc announced that it has submitted a patent application in respect of the Company's bispecific designs for antigen display. The Company uses antigens to generate and screen for specific antibodies during the Antibody Discovery process. Fusion's new designs for antigens consist of two parts; the antigen part and a "reporter" part, referred to as a "bispecific". The Company believes that the use of a reporter part, which can be any number of useful tags for various antibody screening assays, will increase the success rate in identifying highly potent antibodies from Fusion's range of Antibody Discovery technologies.お知らせ • Jul 28Fusion Antibodies plc Appoints Adrian Kinkaid as Chief Executive Officer, Effective 15 August 2022Fusion Antibodies plc announced the appointment of Dr. Adrian Kinkaid as Chief Executive Officer ("CEO"), effective 15 August 2022. Adrian Kinkaid is an experienced life sciences executive with 25 years' experience in life science and biotherapeutics industries. He joins Fusion from Vortex Liquid Biopsy Solutions Ltd. and Vortex Biosciences Inc. (together "Vortex"), a biotech group focused on world class technology for the isolation of high quality circulating tumour cells. As CEO of Vortex, Adrian led the company's development, including management of its business units. Prior to joining Vortex, Adrian worked as CEO at several antibody-based diagnostics companies including BioFab Ltd, and Lumabs BV. He was formerly the Chief Commercial Officer for Promexus Ltd, a protein biotherapeutics company where he developed the corporate strategy for Therapeutic Affimers, culminating in amulti-target dealwith a potential of over $1bn. Adrianwas previously Chief Business Officer of the Aptamer Group,and Strategic Market Development Leader for Abcam plc, the leading provider of research antibodies. Adrian has a PhD in Biochemistry and undertook postdoctoral research with the Institute of Cancer Research, London. As Chairman and founding member of the European Laboratory Research and Innovation Group, Adrian established their Drug Discovery event, which is now the leading conference of its kind in Europe.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent Non-Executive Director Tim Watts was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 01Fusion Antibodies plc Announces Director Changes, Effective 1 March 2022Fusion Antibodies plc, announces that Matthew Baker, PhD, is joining the Board as a Non-Executive Director with effect from 1 March 2022. Matthew is currently a member of the Company's Scientific Advisory Panel, details of which were announced on 14 January 2022. The Company also announces that Dr. Alan Mawson will be stepping down as a Non-Executive Director of the Company with effect from 31 March 2022. Matthew Baker has more than 20 years' experience developing biologics in biotech and pharma companies and is a research expert in B and T-cell immunology, including drug immunogenicity. He co-founded Antitope Ltd, a service based company focused on using proprietary technologies to humanise antibodies, and was the Chief Scientific Officer of Abzena plc, an antibody services company, until 2016. He previously held a Non-Executive Director role at Oxford Genetics Ltd. (trading as Oxgene) and is currently the CEO of NeoPhore Limited, a private company focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Matthew brings detailed immunology, antibody and virus-based mammalian display knowledge to the Board as well as industry and services market insight.お知らせ • Feb 21Fusion Antibodies plc Announces Resignation of Richard Jones as CEOFusion Antibodies plc announced that Richard Jones has resigned from his role as CEO of the Company in order to pursue other opportunities. Richard will remain with the Company while arrangements are put in place for his successor. The Board has initiated a formal search for a new CEO.分析記事 • Jan 25Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Reported Earnings • Dec 09First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: UK£0.023 loss per share (down from UK£0.019 loss in 1H 2021). Revenue: UK£2.44m (up 28% from 1H 2021). Net loss: UK£584.0k (loss widened 24% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 2.4%, compared to a 8.5% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.Reported Earnings • Aug 11Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.032 loss in FY 2020)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: UK£4.17m (up 6.9% from FY 2020). Net loss: UK£2.90m (loss widened 316% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.分析記事 • May 09We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • May 04Fusion Antibodies plc Provides Unaudited Revenue Guidance for the Year Ended March 31, 2021Fusion Antibodies plc provided unaudited revenue guidance for the year ended March 31, 2021. For the year, the company expects revenue of £4.2 million, marginally ahead of market expectations and a 7% increase on FY2020.分析記事 • Mar 17Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%When you buy shares in a company, there is always a risk that the price drops to zero. But when you pick a company that...お知らせ • Feb 16+ 1 more updateFusion Antibodies plc Announces Executive ChangesFusion Antibodies plc announced the appointment of Richard Jones as Chief Executive Officer, replacing Paul Kerr who stands down from the Board with immediate effect in order to pursue other opportunities. Richard Jones joins Fusion from BrYet Limited. As CEO of BrYet, Richard led the company's transition from research group to a start-up biotechnology company.分析記事 • Jan 04Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Nov 22First half 2021 earnings released: UK£0.019 loss per shareThe company reported a solid first half result with improved revenues and control over expenses, although earnings were flat. First half 2021 results: Revenue: UK£1.91m (up 8.7% from 1H 2020). Net loss: UK£471.0k (flat on 1H 2020).お知らせ • Nov 13Fusion Antibodies plc to Report First Half, 2021 Results on Nov 20, 2020Fusion Antibodies plc announced that they will report first half, 2021 results on Nov 20, 2020お知らせ • Sep 19Fusion Antibodies plc Announces Update on R&D ProgrammeFusion Antibodies plc provided an update on the company's research and development programme. The company's proof-of-concept work on the Mammalian Antibody Library Discovery Platform (the "Library") continues to progress according to plan. The company has made progress on the design, expression and validation of SARS-CoV-2 proteins, commonly known as Coronavirus spike proteins. These antigens have been tested by external partners against patient blood samples and show a 100% correlation with results from a leading certified benchmark test. The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates. The company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidates.Is New 90 Day High Low • Sep 19New 90-day high: UK£1.83The company is up 97% from its price of UK£0.93 on 19 June 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 1.0% over the same period.株主還元FABGB Life SciencesGB 市場7D7.7%8.9%0.9%1Y-25.0%-39.1%19.6%株主還元を見る業界別リターン: FAB過去 1 年間で-39.1 % の収益を上げたUK Life Sciences業界を上回りました。リターン対市場: FABは、過去 1 年間で19.6 % のリターンを上げたUK市場を下回りました。価格変動Is FAB's price volatile compared to industry and market?FAB volatilityFAB Average Weekly Movement6.2%Life Sciences Industry Average Movement6.5%Market Average Movement5.1%10% most volatile stocks in GB Market10.4%10% least volatile stocks in GB Market2.7%安定した株価: FAB 、 UK市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: FABの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200024Adrian Kinkaidwww.fusionantibodies.comフュージョン・アンティボディーズ社は、主にがんや感染症を対象とした組換えタンパク質や抗体の研究・開発・製造を、英国、その他の欧州諸国、北米、および国際的に行う受託研究機関です。モノクローナル抗体の探索・開発、抗体配列決定、抗体エンジニアリング、抗体のヒト化および合理的なアフィニティ成熟化プラットフォーム、組換えタンパク質の発現、安定した細胞株の開発およびcGMPスケールアップサービスを提供している。製薬、バイオテクノロジー、獣医、診断、ライフサイエンス研究企業にサービスを提供している。米国国立がん研究所とは、NCIが選択した標的に対する新規抗体の探索にOptiMALを使用するための共同研究契約を結んでいる。Fusion Antibodies plcは2000年に設立され、英国ベルファストに本社を置いている。もっと見るFusion Antibodies plc 基礎のまとめFusion Antibodies の収益と売上を時価総額と比較するとどうか。FAB 基礎統計学時価総額UK£13.13m収益（TTM）-UK£1.47m売上高(TTM)UK£1.60m8.2xP/Sレシオ-8.9xPER（株価収益率FAB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計FAB 損益計算書（TTM）収益UK£1.60m売上原価UK£1.24m売上総利益UK£352.00kその他の費用UK£1.82m収益-UK£1.47m直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.012グロス・マージン22.06%純利益率-91.92%有利子負債／自己資本比率39.0%FAB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/09 15:07終値2026/08/07 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Fusion Antibodies plc 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Robin DavisonAllenby Capital Limited
お知らせ • Jun 22Fusion Antibodies Receives Notice of Allowance for Canadian Patent Application Covering Antibody Library and MethodFusion Antibodies plc announced that the Canadian Intellectual Property Office has issued a notice of allowance in respect of the Company's Canadian patent application no. 3,115,150. The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The patent, once granted, is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation. The Company is also progressing additional patent applications in respect of the OptiMAL Library in Canada and several other territories worldwide including Europe and China. Receipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.
お知らせ • Jun 15Fusion Antibodies plc Receives Grant Funding from UK Research & Innovation and InvestNIFusion Antibodies plc provided the following update on the progress of the InnovateUK Launchpad grant in collaboration with Queen's University Belfast. The primary purpose of the Grant is to develop a humanised antibody targeting and activating the DR5 protein on cancer cells for the treatment of cancers resistant to other therapies, with the aim of producing a clinic-ready therapeutic asset capable of being licensed to a third-party pharmaceutical or biotechnology company. The Grant funds are being provided by UK Research & Innovation and InvestNI. The DR5 antibody has been successfully humanised from the initial rabbit antibody using the Company's proprietary CDRx humanisation platform, and a number of more complex structural variants have been developed and assessed in parallel. All variants are producing positive results in tumour cell death assays, demonstrating the Company's expertise with advanced antibody engineering. The gene encoding the lead humanised antibody has been successfully inserted and developed into a stable cell line suitable for large-scale manufacture. This cell line development part of the process made use of new microfluidic technology housed at the Future Medicines Institute and reduced the process timeline by approximately 50% to around four months. Given the progress made to date, UK Research & Innovation has agreed to extend the project from its originally targeted completion date of October 31, 2026 to December 31, 2026. Over the remaining months of the project, the DR5 humanised antibody and selected variants will undergo further pre-clinical evaluation in relevant cancer models. Positive results are expected to support a patent application covering the antibody family and could lead to the creation of a licensable therapeutic asset for further development and commercialisation by an industry partner. Total Grant funding is over GBP 808,000 of which up to GBP 545,000 of direct non-dilutive funding available to Fusion. Eligible costs include Labour, Overheads and Materials. The project has provided valuable Case Study data for several of Fusion's key technologies including CDRx humanisation, complex protein engineering capability, more rapid cell line development, and the potential to generate a licensable asset. A formal Collaboration Agreement has been signed by Fusion and Queen's University Belfast.
New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£927k net loss next year). Share price has been volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.1m). Market cap is less than US$100m (UK£15.3m market cap, or US$20.5m).
New Risk • Feb 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£789k net loss next year). Share price has been volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.2m). Market cap is less than US$100m (UK£16.9m market cap, or US$23.1m).
Reported Earnings • Nov 27First half 2026 earnings released: UK£0.005 loss per share (vs UK£0.008 loss in 1H 2025)First half 2026 results: UK£0.005 loss per share (improved from UK£0.008 loss in 1H 2025). Revenue: UK£838.0k (down 31% from 1H 2025). Net loss: UK£512.0k (loss narrowed 33% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Nov 21Fusion Antibodies plc to Report First Half, 2026 Results on Nov 24, 2025Fusion Antibodies plc announced that they will report first half, 2026 results on Nov 24, 2025
お知らせ • Jun 22Fusion Antibodies Receives Notice of Allowance for Canadian Patent Application Covering Antibody Library and MethodFusion Antibodies plc announced that the Canadian Intellectual Property Office has issued a notice of allowance in respect of the Company's Canadian patent application no. 3,115,150. The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The patent, once granted, is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation. The Company is also progressing additional patent applications in respect of the OptiMAL Library in Canada and several other territories worldwide including Europe and China. Receipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.
お知らせ • Jun 15Fusion Antibodies plc Receives Grant Funding from UK Research & Innovation and InvestNIFusion Antibodies plc provided the following update on the progress of the InnovateUK Launchpad grant in collaboration with Queen's University Belfast. The primary purpose of the Grant is to develop a humanised antibody targeting and activating the DR5 protein on cancer cells for the treatment of cancers resistant to other therapies, with the aim of producing a clinic-ready therapeutic asset capable of being licensed to a third-party pharmaceutical or biotechnology company. The Grant funds are being provided by UK Research & Innovation and InvestNI. The DR5 antibody has been successfully humanised from the initial rabbit antibody using the Company's proprietary CDRx humanisation platform, and a number of more complex structural variants have been developed and assessed in parallel. All variants are producing positive results in tumour cell death assays, demonstrating the Company's expertise with advanced antibody engineering. The gene encoding the lead humanised antibody has been successfully inserted and developed into a stable cell line suitable for large-scale manufacture. This cell line development part of the process made use of new microfluidic technology housed at the Future Medicines Institute and reduced the process timeline by approximately 50% to around four months. Given the progress made to date, UK Research & Innovation has agreed to extend the project from its originally targeted completion date of October 31, 2026 to December 31, 2026. Over the remaining months of the project, the DR5 humanised antibody and selected variants will undergo further pre-clinical evaluation in relevant cancer models. Positive results are expected to support a patent application covering the antibody family and could lead to the creation of a licensable therapeutic asset for further development and commercialisation by an industry partner. Total Grant funding is over GBP 808,000 of which up to GBP 545,000 of direct non-dilutive funding available to Fusion. Eligible costs include Labour, Overheads and Materials. The project has provided valuable Case Study data for several of Fusion's key technologies including CDRx humanisation, complex protein engineering capability, more rapid cell line development, and the potential to generate a licensable asset. A formal Collaboration Agreement has been signed by Fusion and Queen's University Belfast.
New Risk • Jun 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£927k net loss next year). Share price has been volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.1m). Market cap is less than US$100m (UK£15.3m market cap, or US$20.5m).
New Risk • Feb 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£789k net loss next year). Share price has been volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.2m). Market cap is less than US$100m (UK£16.9m market cap, or US$23.1m).
Reported Earnings • Nov 27First half 2026 earnings released: UK£0.005 loss per share (vs UK£0.008 loss in 1H 2025)First half 2026 results: UK£0.005 loss per share (improved from UK£0.008 loss in 1H 2025). Revenue: UK£838.0k (down 31% from 1H 2025). Net loss: UK£512.0k (loss narrowed 33% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Nov 21Fusion Antibodies plc to Report First Half, 2026 Results on Nov 24, 2025Fusion Antibodies plc announced that they will report first half, 2026 results on Nov 24, 2025
お知らせ • Nov 04Fusion Antibodies plc Provides an Update to the OptiMal ProjectFusion Antibodies plc provides an update to the OptiMAL project being performed under the collaboration agreement with the National Cancer Institute, details of which were originally announced on 28 November 2023. Having already demonstrated superior single digit nM affinities for antibodies against protein targets, as detailed in the announcement on 17 September 2025, the Company can report that OptiMAL has been now shown to be similarly successful with smaller peptide targets. Peptides are often used as antigens as they can be designed to represent specific epitopes (regions of the protein) for the antibodies generated. They are also easier and more cost effective to synthesize. However, they are less immunogenic which can result in poorer antibodies. This is not the case with OptiMAL as no immune response is required. This evidence will better enable Fusion to propose the use of OptiMAL for a wider range of targets, thereby broadening the accessible market and increasing revenue potential. The next steps are to test the antibodies in cell-based assays at the NCI, to evaluate their potential to become therapeutic drug candidates. This latest finding provides further validation of OptiMAL as a platform for the isolation of specific antibodies against proteins and peptides and places the Company on track for the commercial launch of OptiMAL at the Antibody Engineering and Therapeutics conference in December 2025. Work continues within Fusion to further optimise and expand the OptiMAL platform. NCI, part of the US National Institutes of Health, is the US federal government's principal agency for cancer research and training. Pursuant to the Agreement, Fusion has provided NCI with access to OptiMAL for use in the discovery of novel antibodies against targets selected by NCI. This Agreement is due to continue until November 2025, however, the NCI has asked to extend its use of the OptiMAL platform for use against further targets in the coming years. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
お知らせ • Sep 22Fusion Antibodies plc, Annual General Meeting, Oct 16, 2025Fusion Antibodies plc, Annual General Meeting, Oct 16, 2025. Location: the offices of fusion antibodies plc, 1 springbank road, springbank industrial estate, belfast bt17 0ql, United Kingdom
Reported Earnings • Sep 05Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: UK£0.018 loss per share (improved from UK£0.039 loss in FY 2024). Revenue: UK£1.97m (up 73% from FY 2024). Net loss: UK£1.71m (loss narrowed 22% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Jul 25Fusion Antibodies plc Announces That the United States Patent and Trademark Office Has Published A Patent Issue Notification in Respect of Patent Application No. 17/287,441Fusion Antibodies plc announces that the United States Patent and Trademark Office has published a patent issue notification (the "Issue Notification") in respect of the Company's patent application no. 17/287,441 . A patent issue notification is a document informing an applicant that their patent application has been approved and is scheduled to be granted. The Issue Notification indicates that the patent will be granted on 5 August 2025. The Patent Application, entitled "Antibody Library and Method", concerns the library of antibodies that is currently screened within Fusion's OptiMAL® platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide "Opti" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation. Further patent applications and examination processes are continuing in several other territories worldwide including Europe, China and Japan.
New Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£7.56m market cap, or US$10.2m).
お知らせ • May 23Fusion Antibodies plc Provides Update on U.S. Patent for OptimalFusion Antibodies plc announced that the United States Patent and Trademark Office has issued a notice of allowance in respect of the Company's U.S. patent application no. 17/287,441. The Patent Application entitled "Antibody Library and Method", concerns the library of antibodies that is currently screened within Fusion's OptiMAL platform, as well as the method for the design of additional libraries. This is key to Fusion's offering to provide "Opti" designed libraries for a range of applications including Antibody Discovery, Affinity Maturation, and Sequence Optimisation. Receipt of a notice of allowance indicates that the claims in the Patent Application are patentable and does not in itself represent a grant of patent rights. Fusion anticipates that the patent will be granted upon completion of certain administrative requirements, including payment of the Patent Application, in due course.
New Risk • Apr 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£7.71m market cap, or US$10.3m).
お知らせ • Mar 18Fusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.172153 million.Fusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.172153 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,949,208 Price\Range: £0.0675 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,416,020 Price\Range: £0.0675 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 31Fusion Antibodies plc Provides an Update on the Optimal Validation ProjectFusion Antibodies plc provided an update on the OptiMAL® validation project being performed under the collaboration agreement (the "Agreement") with the National Cancer Institute ("NCI"). The validation project is progressing as planned and, using Fusion's OptiMAL® Library, the NCI has identified a number of antibody expressing cells that positively bind to their targets of interest. Fusion will extract and sequence the DNA encoding for the antibodies from these cells for verification of binding and further analyses. This analysis will take several months. The Company has received the first batch of cells from the NCI that have been isolated from the OptiMAL® Library for this validation work and additional batches will be shipped subsequently. Fusion is undertaking this work on a goodwill basis to assist the validation of the OptiMAL® Library. The NCI will continue the process of identifying more positive cells against their various targets and the Company also anticipates assisting in the analysis of the antibodies produced from these cells. NCI, part of the US National Institutes of Health, is the US federal government's principal agency for cancer research and training. Pursuant to the Agreement, details of which were announced by the Company on 28 November 2023, Fusion has provided NCI with access to OptiMAL® for use in the discovery of novel antibodies against targets selected by NCI.
Reported Earnings • Nov 25First half 2025 earnings released: UK£0.008 loss per share (vs UK£0.029 loss in 1H 2024)First half 2025 results: UK£0.008 loss per share (improved from UK£0.029 loss in 1H 2024). Revenue: UK£1.21m (up 123% from 1H 2024). Net loss: UK£758.0k (loss narrowed 44% from 1H 2024).
お知らせ • Nov 20Fusion Antibodies plc to Report First Half, 2025 Results on Nov 19, 2024Fusion Antibodies plc announced that they will report first half, 2025 results on Nov 19, 2024
New Risk • Sep 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.8m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (UK£3.86m market cap, or US$5.18m). Minor Risk Revenue is less than US$5m (UK£1.1m revenue, or US$1.5m).
お知らせ • Sep 12Fusion Antibodies plc, Annual General Meeting, Oct 08, 2024Fusion Antibodies plc, Annual General Meeting, Oct 08, 2024. Location: the offices of fusion antibodies, 1 springbank road, springbank industrial estate, belfast, bt17 0ql, United Kingdom
Reported Earnings • Sep 06Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: UK£0.039 loss per share (improved from UK£0.10 loss in FY 2023). Revenue: UK£1.14m (down 61% from FY 2023). Net loss: UK£2.23m (loss narrowed 14% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 26%.
New Risk • Jun 21New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Market cap is less than US$10m (UK£3.19m market cap, or US$4.04m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (7.2% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.0m).
お知らせ • Feb 14+ 1 more updateFusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.375 million.Fusion Antibodies plc has completed a Follow-on Equity Offering in the amount of £1.375 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 34,375,000 Price\Range: £0.04 Transaction Features: Subsequent Direct Listing
Reported Earnings • Dec 07First half 2024 earnings released: UK£0.023 loss per share (vs UK£0.043 loss in 1H 2023)First half 2024 results: UK£0.023 loss per share. Revenue: UK£541.0k (down 71% from 1H 2023). Net loss: UK£1.36m (loss widened 22% from 1H 2023).
お知らせ • Dec 05Fusion Antibodies plc to Report First Half, 2024 Results on Dec 04, 2023Fusion Antibodies plc announced that they will report first half, 2024 results on Dec 04, 2023
お知らせ • Dec 04Fusion Antibodies plc Provides Revenue Guidance for the Fiscal Year 2024Fusion Antibodies plc provided revenue guidance for the fiscal year 2024. For the year, the revenues are expected to be significantly weighted towards the second half of the financial year. This is supported by the revenue growth trend observed through first half of fiscal year 2024 and the marked growth in its sales opportunities pipeline over the last six months.
お知らせ • Nov 09Fusion Antibodies plc Provides Earnings Guidance for the First Half of Fiscal Year 2024Fusion Antibodies plc provided earnings guidance for the first half of fiscal year 2024. For the period, the company expects revenue to be behind current market expectations, at not less than £541,000.
New Risk • Oct 01New major risk - Revenue and earnings growthEarnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Market cap is less than US$10m (UK£3.27m market cap, or US$3.99m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Revenue is less than US$5m (UK£2.9m revenue, or US$3.5m).
Reported Earnings • Oct 01Full year 2023 earnings released: UK£0.10 loss per share (vs UK£0.046 loss in FY 2022)Full year 2023 results: UK£0.10 loss per share (further deteriorated from UK£0.046 loss in FY 2022). Revenue: UK£2.90m (down 40% from FY 2022). Net loss: UK£2.60m (loss widened 116% from FY 2022).
お知らせ • Oct 01Fusion Antibodies plc Announces Sonya Ferguson, Non-Executive Director, Will Not Be Seeking Re-Election At the AGMFusion Antibodies plc announced that Sonya Ferguson, Non-executive Director, will not be seeking re-election at the AGM to be held on 27 October 2023, as she has decided to pursue another business opportunity. She will cease to be a Director of the Company at the close of the AGM.
お知らせ • Sep 29Fusion Antibodies plc, Annual General Meeting, Oct 27, 2023Fusion Antibodies plc, Annual General Meeting, Oct 27, 2023, at 10:00 Coordinated Universal Time. Location: Springbank Industrial Estate, 1 Springbank Rd Dunmurry Belfast United Kingdom
お知らせ • Aug 24Fusion Antibodies plc Appoints Stephen Smyth as Interim Chief Financial Officer of the Company with Immediate EffectFusion Antibodies plc announces that Stephen Smyth has been appointed as interim Chief Financial Officer of the Company with immediate effect. Stephen has over 25 years' experience working in audit & accounting, finance, and operations management within both the public accounting and commercial sectors. Stephen's previous roles include acting as Chief Financial Officer at Sera Global LP, as well as holding senior finance functions at Cormark Securities Inc. and at PricewaterhouseCoopers (PwC) LLP. Stephen is a chartered accountant and is currently a partner at FPM, a Chartered Accountancy practice with offices throughout the Republic of Ireland and Northern Ireland, including Belfast. At FPM, he provides virtual finance function solutions to clients ranging from start-ups to private equity backed multinationals. As part of the ongoing efforts to preserve cash, Fusion will be utilising the services of Stephen on a part-time basis, supported by a team at FPM, who will provide the Company with outsourced finance function services. It is anticipated that the Company will utilise the services of Stephen and FPM until such time that the trading recovers to levels that would support the appointment of a permanent CFO and in-house finance function.
お知らせ • Aug 21Fusion Antibodies plc Announces an Update on the AI/ML-Ab Service OfferingFusion Antibodies plc announced an update on the Company's AI/ML-Ab (pronounced AIM-Lab) service offering. On 19 May 2023, the Company announced that it had signed memoranda of understanding with two AI/ML (artificial intelligence and machine learning) companies. The Company announced that is has now signed an agreement with the first of the companies, a leading US-based AI/ML business, to support Fusion's new AI/ML-Ab service offering. Pursuant to the Agreement, it is envisaged that both parties will co-market the combined service offerings covering both the in silico AI/ML design of antibodies and their production and evaluation in vitro. Each party to the Agreement will be entitled to a fee for any new business introduced to the other. Both parties have already combined to begin commercialisation of the offering and are processing multiple leads derived by both entities. AI/ML-Ab combines the latest AI enabled technology for in silico design of antibody sequences with Fusion's established core expertise in antibody expression and evaluation. Furthermore, AI/ML-Ab can also employ Fusion's recently announced proprietary Mammalian Display platform to enable screening of focused libraries derived from AI/ML design outputs. By combining the two approaches, clients will be able to screen thousands or even millions of sequences rather than the tens or hundreds to which such projects tend to be restricted. Increasing the number of sequences to be screened by a factor of 1,000 or more significantly enhances the prospects of finding the most appropriate leads from AI/ML discovery projects, not only de-risking this novel cutting-edge approach to antibody discovery but also achieving this at a significantly lower cost per sequence. Fusion collaborates with its clients in every stage of pre-clinical antibody development, with decades of experience and unique proprietary platforms. A fully integrated end-to-end service from therapeutic target nomination and discovery through to stable cell line development in readiness for GMP production is also available. The Company is continuing to work on other aspects of the OptiMAL programme, and in particular the development of the fully human antibody library.
お知らせ • Feb 09Fusion Antibodies plc Launches New Commercial Service from Its R&D ProgrammeFusion Antibodies plc announced that is has launched a new commercial service from its R&D programme, named Mammalian Display, for high volume mammalian cell surface expression and screening of antibodies. Mammalian Display is the first service from the Company's ongoing OptiMAL programme which Fusion has commercialised and is now offering to clients. The service is particularly suited to companies specialising in the identification of therapeutic antibodies from focussed libraries of sequences, such as would be required by those entities using artificial intelligence or machine learning which can require the expression and screening of small libraries of tens of thousands of antibodies. Fusion collaborates with its clients in every stage of pre-clinical antibody development, with decades of experience and unique proprietary platforms. A fully integrated end-to-end service from therapeutic target nomination and discovery through to stable cell line development in readiness for GMP production is also available. Initial market research that the Company has conducted with AI/ML experts has confirmed that there is a need for expression of focussed libraries of antibodies in the way delivered by the Mammalian Display service. The Company is continuing to work on other aspects of the OptiMAL programme, and in particular the development of the fully human antibody library.
Reported Earnings • Dec 06First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.023 loss in 1H 2022)First half 2023 results: UK£0.043 loss per share (further deteriorated from UK£0.023 loss in 1H 2022). Revenue: UK£1.86m (down 24% from 1H 2022). Net loss: UK£1.12m (loss widened 91% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 19% per year.
お知らせ • Nov 24Fusion Antibodies plc to Report First Half, 2023 Results on Dec 05, 2022Fusion Antibodies plc announced that they will report first half, 2023 results on Dec 05, 2022
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Member of Scientific Advisory Panel & Independent Non-Executive Director Matthew Baker was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 02Fusion Antibodies plc, Annual General Meeting, Sep 23, 2022Fusion Antibodies plc, Annual General Meeting, Sep 23, 2022, at 10:00 Coordinated Universal Time. Location: in The Malone Hotel, 60 Eglantine Avenue, Malone Road Belfast, BT9 6DY Belfast Ireland
お知らせ • Sep 01Fusion Antibodies plc Announces Director ChangesFusion Antibodies plc announced Tim Watts, Non-executive Director since December 2017, has informed the Board of his intention to retire and, therefore, will not be seeking re-election at the AGM. He will cease to be a Director of the Company at the close of the AGM. Colin Walsh, Non-executive Director will take up the position of Chair of the Company's Audit Committee in place of Tim Watts.
分析記事 • Aug 31Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • Aug 23Full year 2022 earnings released: UK£0.046 loss per share (vs UK£0.11 loss in FY 2021)Full year 2022 results: UK£0.046 loss per share (up from UK£0.11 loss in FY 2021). Revenue: UK£4.80m (up 15% from FY 2021). Net loss: UK£1.20m (loss narrowed 59% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
お知らせ • Aug 09Fusion Antibodies plc Announces Bispecific Designs Patent ApplicationFusion Antibodies plc announced that it has submitted a patent application in respect of the Company's bispecific designs for antigen display. The Company uses antigens to generate and screen for specific antibodies during the Antibody Discovery process. Fusion's new designs for antigens consist of two parts; the antigen part and a "reporter" part, referred to as a "bispecific". The Company believes that the use of a reporter part, which can be any number of useful tags for various antibody screening assays, will increase the success rate in identifying highly potent antibodies from Fusion's range of Antibody Discovery technologies.
お知らせ • Jul 28Fusion Antibodies plc Appoints Adrian Kinkaid as Chief Executive Officer, Effective 15 August 2022Fusion Antibodies plc announced the appointment of Dr. Adrian Kinkaid as Chief Executive Officer ("CEO"), effective 15 August 2022. Adrian Kinkaid is an experienced life sciences executive with 25 years' experience in life science and biotherapeutics industries. He joins Fusion from Vortex Liquid Biopsy Solutions Ltd. and Vortex Biosciences Inc. (together "Vortex"), a biotech group focused on world class technology for the isolation of high quality circulating tumour cells. As CEO of Vortex, Adrian led the company's development, including management of its business units. Prior to joining Vortex, Adrian worked as CEO at several antibody-based diagnostics companies including BioFab Ltd, and Lumabs BV. He was formerly the Chief Commercial Officer for Promexus Ltd, a protein biotherapeutics company where he developed the corporate strategy for Therapeutic Affimers, culminating in amulti-target dealwith a potential of over $1bn. Adrianwas previously Chief Business Officer of the Aptamer Group,and Strategic Market Development Leader for Abcam plc, the leading provider of research antibodies. Adrian has a PhD in Biochemistry and undertook postdoctoral research with the Institute of Cancer Research, London. As Chairman and founding member of the European Laboratory Research and Innovation Group, Adrian established their Drug Discovery event, which is now the leading conference of its kind in Europe.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Independent Non-Executive Director Tim Watts was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 01Fusion Antibodies plc Announces Director Changes, Effective 1 March 2022Fusion Antibodies plc, announces that Matthew Baker, PhD, is joining the Board as a Non-Executive Director with effect from 1 March 2022. Matthew is currently a member of the Company's Scientific Advisory Panel, details of which were announced on 14 January 2022. The Company also announces that Dr. Alan Mawson will be stepping down as a Non-Executive Director of the Company with effect from 31 March 2022. Matthew Baker has more than 20 years' experience developing biologics in biotech and pharma companies and is a research expert in B and T-cell immunology, including drug immunogenicity. He co-founded Antitope Ltd, a service based company focused on using proprietary technologies to humanise antibodies, and was the Chief Scientific Officer of Abzena plc, an antibody services company, until 2016. He previously held a Non-Executive Director role at Oxford Genetics Ltd. (trading as Oxgene) and is currently the CEO of NeoPhore Limited, a private company focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Matthew brings detailed immunology, antibody and virus-based mammalian display knowledge to the Board as well as industry and services market insight.
お知らせ • Feb 21Fusion Antibodies plc Announces Resignation of Richard Jones as CEOFusion Antibodies plc announced that Richard Jones has resigned from his role as CEO of the Company in order to pursue other opportunities. Richard will remain with the Company while arrangements are put in place for his successor. The Board has initiated a formal search for a new CEO.
分析記事 • Jan 25Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Reported Earnings • Dec 09First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: UK£0.023 loss per share (down from UK£0.019 loss in 1H 2021). Revenue: UK£2.44m (up 28% from 1H 2021). Net loss: UK£584.0k (loss widened 24% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 2.4%, compared to a 8.5% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 11Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.032 loss in FY 2020)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: UK£4.17m (up 6.9% from FY 2020). Net loss: UK£2.90m (loss widened 316% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
分析記事 • May 09We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • May 04Fusion Antibodies plc Provides Unaudited Revenue Guidance for the Year Ended March 31, 2021Fusion Antibodies plc provided unaudited revenue guidance for the year ended March 31, 2021. For the year, the company expects revenue of £4.2 million, marginally ahead of market expectations and a 7% increase on FY2020.
分析記事 • Mar 17Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%When you buy shares in a company, there is always a risk that the price drops to zero. But when you pick a company that...
お知らせ • Feb 16+ 1 more updateFusion Antibodies plc Announces Executive ChangesFusion Antibodies plc announced the appointment of Richard Jones as Chief Executive Officer, replacing Paul Kerr who stands down from the Board with immediate effect in order to pursue other opportunities. Richard Jones joins Fusion from BrYet Limited. As CEO of BrYet, Richard led the company's transition from research group to a start-up biotechnology company.
分析記事 • Jan 04Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Nov 22First half 2021 earnings released: UK£0.019 loss per shareThe company reported a solid first half result with improved revenues and control over expenses, although earnings were flat. First half 2021 results: Revenue: UK£1.91m (up 8.7% from 1H 2020). Net loss: UK£471.0k (flat on 1H 2020).
お知らせ • Nov 13Fusion Antibodies plc to Report First Half, 2021 Results on Nov 20, 2020Fusion Antibodies plc announced that they will report first half, 2021 results on Nov 20, 2020
お知らせ • Sep 19Fusion Antibodies plc Announces Update on R&D ProgrammeFusion Antibodies plc provided an update on the company's research and development programme. The company's proof-of-concept work on the Mammalian Antibody Library Discovery Platform (the "Library") continues to progress according to plan. The company has made progress on the design, expression and validation of SARS-CoV-2 proteins, commonly known as Coronavirus spike proteins. These antigens have been tested by external partners against patient blood samples and show a 100% correlation with results from a leading certified benchmark test. The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates. The company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidates.
Is New 90 Day High Low • Sep 19New 90-day high: UK£1.83The company is up 97% from its price of UK£0.93 on 19 June 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 1.0% over the same period.
